Session Overview
In this webinar, Dr. Dana Upton from Eva Garland Consulting (EGC) explains the NSF SBIR/STTR program and how early-stage startups can use non-dilutive funding to potentially overcome the “valley of death” in R&D. It covers the program’s purpose, the differences between SBIR and STTR, the stages of funding from Project Pitch to Phase I and Phase II, and provides practical tips for creating competitive applications, managing grants, and building sustainable, innovative businesses.
Session Recap
- Early-stage startups face a funding gap often referred to as the “Valley of Death,” where capital is scarce during critical R&D phases.
- Venture capital (VC) is highly selective; only a small percentage of startups receive early-stage VC funding.
- VC funding often favors specific sectors (software, telecom, internet) and geographies (California, Massachusetts), sometimes requiring relocation.
- The Valley of Death exists because critical R&D needs funds before commercial viability, a stage often overlooked by VCs.
- Non-dilutive funding (grants and contracts) provides capital without requiring equity or ownership transfer.
- The federal government allocates billions annually; SBIR/STTR programs total approximately $3 billion across 11 agencies.
- Benefits include the ability to fund multiple projects concurrently and improved survival rates; 99% of grant-funded companies are still operational after five years.
- VC funding is typically tied to one product and requires giving up some control or equity.
- Non-dilutive funding allows companies to retain control, pursue multiple innovations, and focus on sustainable growth.
- VC often favors established markets, while non-dilutive funding encourages high-risk, high-reward, innovative technologies.
- NSF has broader interests (e.g., non-medical robotics, AI, blockchain) compared to NIH’s medical focus.
- NSF Phase I budget is standardized ($305,000), while NIH budgets may vary by institute and project.
- NSF emphasizes commercialization strategy from Phase I onward; NIH focuses on scientific development and clinical research.
- NSF allows direct grant dollars for accounting; NIH requires indirect costs for similar activities.
- Payment structure differs: NSF disburses a lump sum upfront, while NIH operates on reimbursement via invoices.
- Designed to stimulate innovation, entrepreneurship, and private sector participation in federal R&D.
- Focuses on unproven, leading-edge technologies requiring intensive R&D.
- Requires developing a sustainable business and a product with potential to disrupt markets or create new ones.
- Project Pitch: Initial pre-application to demonstrate alignment with NSF mandate; submitted year-round; 3500 characters each for innovation and Phase I plan sections, and 1750 characters for market and company sections.
- Phase I Application: $305,000 for 12–18 months; includes 15-page project description, one-page summary, budget and justification, bios, synergistic activities, data management plan, IP rights agreement (for STTR), and letters of commitment.
- Phase II Application: $1.25 million; requires Phase I completion; includes 15 pages for Phase I final report, project description, and commercialization plan.
- Phase IIB Supplement: Additional funding (up to $0.5M) with cost matching; consult program director before applying.
- NSF review takes 3–6 months; pre-award negotiations involve technical and financial clarifications.
- Intellectual Merit: Novel, innovative research; not incremental improvements.
- Commercial Potential: Clear path to sustainable business and market impact.
- Societal Impact: Broad benefits including job creation.
- High-risk, high-reward projects encouraged, even at early feasibility stage.
- Read the NSF solicitation carefully and follow current rules.
- Start registrations early (SAM.gov, SBA, Research.gov).
- Seek expert guidance and feedback on the application.
- Tell a clear, compelling story using the seven C’s: complete, clear, concise, consistent, correct, considerate, convincing.
- Include figures to enhance clarity and engage reviewers.
- Understand your budget, including direct, indirect, and small business fee allocations.
- Confirm eligibility: US-based, for-profit, <500 employees, appropriate VC ownership.
- Assess readiness: Stage should be feasibility, refinement, or demonstration—not concept-only or near-commercialization.
- Clearly define innovation and competitive advantage.
- Map development path from current stage to envisioned final product.
- Integrate NSF funding into broader business strategy.
- Ensure sufficient time commitment for proposal preparation (estimates ~100 hours for Phase I).
- Non-Dilutive: No equity given up; maintain control of company, IP, and location.
- Founder-Friendly: Terms favor the entrepreneur, flexible use of funds.
- Expert Feedback: Reviewers and program directors provide guidance and coaching.
- Prestige: NSF award signals technical and commercial merit to investors.
- Financial Impact: Phase I and Phase II funding plus potential for follow-on VC and private investment.
